Key statistics
On Friday, Prime Medicine Inc (PRME:NMQ) closed at 3.51, 7.01% above its 52-week low of 3.28, set on Oct 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.41 |
---|---|
High | 3.65 |
Low | 3.40 |
Bid | 3.52 |
Offer | 3.68 |
Previous close | 3.41 |
Average volume | 4.76m |
---|---|
Shares outstanding | 120.03m |
Free float | 88.68m |
P/E (TTM) | -- |
Market cap | 421.31m USD |
EPS (TTM) | -2.16 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 21:00 BST.
More ▼
Announcements
- Prime Medicine Unveils Strategically Focused Pipeline
- Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine to Present at Upcoming Investor Conferences
- Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
- Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
More ▼